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The tumour-suppressive function of CLU is explained
by its localisation and interaction with HSP60
K-A Chaiwatanasirikul1 and A Sala*,1
The product of the CLU gene promotes or inhibits tumourigenesis in a context-dependent manner. It has been hypothesised that
different CLU isoforms have different and even opposing biological functions, but this theory has not been experimentally
validated. Here we show that molecules involved in survival pathways are differentially modulated by the intracellular or secreted
forms of CLU. Secreted CLU, which is selectively increased after transformation, activates the survival factor AKT, whereas
intracellular CLU inhibits the activity of the oncogenic transcription factor nuclear factor kappa B. Furthermore, intracellular CLU
is inactivated by the pro-proliferative and pro-survival activity of the chaperone protein HSP60 in neuroblastoma cells by forming
a physical complex. Thus, localisation is key for CLU physiology, explaining the wide range of effects in cell survival and
transformation.
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CLU (also known as Clusterin, Apolipoprotein J, TRPM-2 and
SGP-2) is a ubiquitously expressed protein involved in the
regulation of cell survival and modulation of tumourigenesis.1
The 449-amino-acid primary polypeptide chain of human CLU
is proteolytically cleaved into the alpha and beta chains
forming an heterodimer held together by disulphide bridges.
CLU is glycosylated before secretion and is highly conserved
in different species, showing a 70–80% protein homology in
mammals.2 CLU expression is low in normal conditions but is
induced by stress stimuli, suggesting that its function could be
directly or indirectly related to the stress response. Mouse
development is not affected by genetic inactivation of CLU;
however, CLU-null mice show increased sensitivity to auto-
immune myocarditis, suggesting a role for CLU in protecting the
heart tissue from postinflammatory destruction.3 In contrast,
neuronal cells are sensitised by CLU to hypoxic injury.4 In many
instances, CLU has been shown to be antiapoptotic, protecting
cells against a variety of death signals. Exogenous CLU
protects tumour cells from cytokine- or drug-induced apoptosis,
and inhibition of CLU results in the increased sensitivity of
cancer cells to chemotherapeutic drugs.5–11
How CLU exerts its function has been matter of speculation.
One hypothesis is that CLU is involved in the clearance of toxic
substances from extracellular spaces through its ability to bind to
unfolded proteins and cell debris or immune complexes.12,13
CLU binds to the endocytic receptor megalin (LRP-2), and the
clearance effect could be achieved by internalisation of the
receptor–ligand complex and lysosomal degradation of the toxic
substances.1,2 Apart from its role as a ‘extracellular chaperone’,
CLU may act as a signalling molecule: CLU has been shown
to activate or suppress phosphoinositide-3-kinase-AKT or
MAP/ERK signalling pathways in different studies.11,14–17
The ability of CLU to modulate proliferative and survival
pathways probably explains the plethora of biological
functions attributed to this molecule. For example, CLU can
relieve disease-induced inflammation by interfering with
nuclear factor kappa B (NF-kB) activity via direct physical
contact with inhibitors of Kappa B.18 In cancer, we have shown
that CLU exerts a tumour-suppressive role by suppressing
NF-kB.19–21 NF-kB is a transcription factor central to cellular
processes such as cell survival and proliferation, immunity
and tumourigenesis.22 Mouse embryo fibroblasts with a
disrupted CLU gene show IKB destabilisation, which results
in increased NF-kB activity and modulation of NF-kB-target
genes.21 CLU KO mice show increased susceptibility to
cancer,19,20,23 but the tumour-suppressive function of CLU is
sometimes ad odds with reports in which CLU has been
shown to be increased in aggressive forms of human cancer.
How can CLU function as a tumour suppressor and oncogene
at the same time?
One hypothesis investigated in this study is that CLU exerts
distinct functions in different locations. For example, nuclear
CLU has been shown to promote apoptosis, and to inhibit
prostate cancer cell proliferation.24–26 In neuroblastoma, the
expression of nuclear CLU is marginal and we have only
observed this variant in terminally necrotic or apoptotic cells,
suggesting that its expression is a consequence rather a
cause of cell death in physiological conditions.20 Instead, CLU
is detectable in the cytoplasm, extracellular spaces or the
Golgi apparatus and it is not known whether its localisation
also affects its biological function.20 We hypothesised that the
controversial role that CLU has in cancer could be explained if
the expression of intracellular and extracellular CLU has
different biological outcomes.
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The purpose of this study was to understand the function of
intracellular and secreted CLU in the context of neuroblastoma.
We show here that secreted and intracellular CLU has distinct
properties, which could explain, at least in part, the enigmatic
role of CLU in cancer.
Results
Intracellular and secreted CLU isoforms modulate distinct
signalling molecules and their relative expression
changes during transformation. To investigate whether
CLU signalling is determined by its intracellular or extra-
cellular localisation, we prepared supernatants from 293 cells
transfected with a CLU expression vector that we used as a
source of extracellular CLU (Supplementary Figure 1), and
used these supernatants in luciferase assays in which we
assessed the activity of a NF-kB reporter vector. Tumour
necrosis factor (TNF) was used to activate NF-kB activity and
served as a positive control. Secreted CLU was unable to inhibit
basal or TNF-induced NF-kB activity in two neuroblastoma cell
lines, although LA-N-1 cells were unresponsive to TNF (Figures
1a and b). This experiment was further validated by culturing
cells in the presence of purified CLU obtained from a
commercial source with the identical results (not shown).
In contrast, NF-kB activity was inhibited after transiently
transfecting the CLU expression plasmid into the same
neuroblastoma cell lines, suggesting that only intracellular
CLU is able to inhibit NF-kB (Figures 1c and d). Next, we
investigated whether lack of signalling activity of secreted CLU
was intrinsic or related to the extracellular localisation. We
stimulated two neuroblastoma cell lines with control or CLU-
containing medium and monitored the activation of the signalling
molecules AKT and ERK. Extracellular CLU caused sustained
activation of AKT, but not of ERK, suggesting that extracellular
CLU, as previously reported,6,14 is a specific activator of the pro-
survival Pi3K–AKT axis (Figures 2a and b). Again, the result
was validated with purified CLU (data not shown). To investigate
whether the expression of intracellular and secreted CLU
changes during transformation, we monitored the ratio of the
60 kDa intracellular precursor and 35 kDa secreted CLU iso-
forms in isogenic variants of primary human fibroblasts before
and after SV40 transformation. Interestingly, expression of the
intracellular precursor is dramatically decreased in transformed
VA13 compared with non-transformed WI38 cells (Figure 2c).
Furthermore, expression of precursor CLU is undetectable in
primary neuroblastoma tumours from MYCN transgenic mice,
whereas it is clearly visible in adrenal glands, the corresponding
normal tissue (Figure 2d).
Figure 1 Secreted CLU is unable to modulate NF-kB activity. (a) SHSY5Y or (b) LA-N-1 neuroblastoma cells were transfected with a NF-kB luciferase reporter vector,
incubated with control or CLU-conditioned medium, as indicated in the bottom of the graphs, and subjected to luciferase assays. Activation of NF-kB by TNF served as a
positive control for the assay. Relative luciferase activity is indicated on the y axis. (c) SHSY5Y or (d) LA-N-1 cells were co-transfected with the NF-kB reporter vector and a
control (empty MIG), or CLU, expressing plasmid with or without TNF. Error bars indicate standard deviations, and significance is indicated by the P. NS indicates that the
difference is not significant
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Identification of proteins interacting with CLU in
neuroblastoma cells. To gain more insights on the role of
intracellular CLU in molecular signalling, we carried out pull-
down experiments to determine which cellular proteins bind
to CLU in neuroblastoma cells. Full length or the alpha and
beta chain CLU were fused to glutathione S transferase
(GST), and cellular proteins were pulled down and visualised
by silver staining. Several cellular proteins (indicated by an
asterisk) bound the fusion proteins, but not GST alone. We
decided to further investigate a protein of about 60 kDa that
was binding to the full-length CLU polypeptide and its alpha
chain but not the beta chain (Figure 3a). Protein bands
obtained from the pull down with full length and alpha chain
were excised and subjected to mass spectrometry analysis.
As expected, more than one polypeptide was present in the
excised bands and the presence of keratin, a classical
contaminant in pull-down assays, was not further investi-
gated. A fragment of LRP2, also known as megalin and a
known CLU receptor, was identified in the band excised from
full-length CLU. The presence of megalin was an indication of
the success of the assay. We next focused our interest on
HSP60, which was found in the protein bands pulled down by
both full-length- and alpha chain CLU–GST fusion proteins
(Supplementary Figure 2). HSP60 is a chaperone molecule
with a role in tumourigenesis and has been recently shown to
be an activator of NF-kB.27,28 Thus, its presence in the CLU-
binding assay suggested that the interaction could be
physiologically relevant.
Firstly, we mapped the domain of CLU responsible for the
interaction with HSP60 by pull-down and western blot assay
with a HSP60 antibody. We observed that CLU full length and
alpha chain were more efficient than the beta chain in binding
to HSP60, confirming that the alpha chain of CLU is the major
interacting domain. As expected GST alone did not bind to
HSP60 further demonstrating that the interaction is specific to
CLU (Figure 3b). We next assessed whether the interaction
was detectable by co-immunoprecipitation assays in living
cells. We transfected CLU into 293 cells and observed that
exogenously expressed CLU co-immunoprecipitated with
endogenous HSP60 in vivo (Figure 3c). Detection of a native
CLU/HSP60 complex in neuroblastoma cells is complicated
by the very low expression levels of CLU in this tumour.20 To
overcome this problem, we subjected LA-N-1 neuroblastoma
cells to heat shock, which greatly enhances the expression of
endogenous CLU (Figure 4a). In these conditions, a native
complex containing HSP60 and CLU is detectable in
neuroblastoma cells using reciprocal antibodies demonstrat-
ing that their interaction is genuine (Figure 4b).
The CLU-interacting protein HSP60 promotes cell
survival and is a marker of poor prognosis in
neuroblastoma. We firstly investigated whether HSP60
could have a role in neuroblastoma by assessing the effect
of its knockdown using RNA interference. To this end, we
generated SHSY5Y-independent clones with reduced
expression of HSP60. In all, three out of three of the
interfered cells lines proliferated less than a scrambled
control clone (Figures 5a–c). It is likely that reduced
proliferation is caused by increased apoptosis, as the
HSP60-interfered clones showed enhanced annexin
staining as compared with control cells (Supplementary
Figure 3). We extended the significance of these results by
inducing HSP60 downregulation in primary human
neuroblastoma cells isolated from a metastasis of a stage 4
Figure 2 Secreted CLU modulates AKT and is increased relative to intracellular CLU during transformation. (a) Western blot analysis of phosphorylated and total AKT in
the indicated neuroblastoma cell lines. Hours of stimulation with control or CLU-conditioned media (CLU-MIG) are indicated on the top of the blots. (b) Western blot analysis of
phosphorylated and total ERK in the indicated neuroblastoma cell lines. Hours of stimulation with the control or CLU-conditioned media are indicated on the top of the blots.
(c) Western blot analysis of CLU expression in the isogenic cell lines WI38 (primary human fibroblasts) and VA13 (SV40-transformed WI38). (d) Western blot analysis of the
expression of CLU in the adrenal glands and tumours resected from MYCN transgenic mice. pCLU, precursor CLU; sCLU, secreted CLU
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patient. We confirmed that HSP60 was expressed in these
primary cells, and the infection with a lentiviral shRNA vector
caused a drastic downregulation of HSP60 expression
(Figure 5d). Ablation of HSP60 caused reduced prolifer-
ation, increased fragmentation of DNA, diagnostic of
apoptosis, but no changes in the cell cycle profiles, further
suggesting that a primary role of HSP60 is to promote cell
survival (Figures 5e and f).
To investigate whether HSP60 expression is clinically
relevant, we verified that expression of HSP60 is higher in
patients with amplification of the adverse prognostic marker
MYCN (Figure 6a). Furthermore, HSP60 expression is
associated with poor survival in neuroblastoma patients
(Figures 6b and c).
HSP60 promotes neuroblastoma cell survival by
antagonising CLU. As expression of CLU is inversely
correlated with that of MYCN and it marks patients with
better probability of survival,20 we hypothesised that the
physical interaction between CLU and HSP60 could be
antagonistic. To directly address this point, we generated
neuroblastoma cell lines with downregulation of HSP60, CLU
or both HSP60 and CLU (Supplementary Figure 4). If CLU is
a downstream target of HSP60, its knockout should rescue
the apoptotic phenotype that follows HSP60 ablation. Indeed,
we observed that DNA fragmentation caused by reduced
levels of HSP60 was generally rescued by ablation of CLU
in SHSY5Y clones in two independent experiments, further
corroborating the hypothesis that CLU is a critical down-
stream target of HSP60 antiapoptotic activity (Figures 7a and b).
HSP60 is an activator of NF-kB in mammalian cells and, in
keeping with these results, we observed that reducing HSP60
levels causes decreased NF-kB activity in both SHSY-5Y and
primary neuroblastoma cells (Figures 8a and b). Interestingly,
analysis of affymetrix databases available through the
Oncomine website shows that expression of HSP60 is
associated with that of NF-kB target genes in neuroblastoma
patients, suggesting that one of the mechanisms by which
HSP60 behave as a neuroblastoma oncogene could be
related to its ability to activate NF-kB signalling (Figure 8c). In
agreement with this hypothesis, knockdown of HSP60 causes
upregulation of CLU expression indicating that, in addition to
Figure 3 Identification of HSP60 as a CLU-interacting protein. (a) proteins pulled down by the indicated GST fusion proteins were visualised by colloidal Coomassie
staining. A protein ofB60 kDa interacting with full length and alpha chain CLU (indicated by the arrow) was excised from the gel and subjected to mass spectrometry analysis.
(b) Proteins pulled down by the indicated fusion proteins were subjected to western blot analysis with a HSP60 antibody. (c) Co-immunoprecipitation assay. 293 cells were
transfected with control or CLU plasmids, lysed and immunoprecipitated with CLU, HSP60 or control antibodies. After transfer to nitrocellulose, immune complexes were
subjected to western blot analysis with a HSP60 antibody. Specific binding proteins are indicated by an asterisk
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other mechanisms, HSP60 could activate NF-kB by antag-
onising CLU (Figure 8d). A model of the HSP60–CLU axis
operating in neuroblastoma is shown in Figure 8e.
Discussion
A plethora of conflicting observations about the physiological
role of CLU has complicated the understanding of its function
in tumourigenesis. Although some of the discrepancies could
be caused by the use of different experimental settings and
reagents, we speculated that CLU exerts pleiotropic effects in
cancer that could be strictly context dependent.29 A further
level of complexity results from the intricate regulation of CLU
isoforms, which can be found in multiple cellular compartments
(i.e., nucleous, cytoplasm, mitochondria, Golgi, endoplasmic
reticulum) or in the extracellular spaces and the body fluids.
In this study we tried to dissect the physiological role of
intracellular and extracellular CLU. The hypothesis that the
biological function of secreted CLU could be different from that
of intracellular CLU is based on several points of evidence.
For example, in prostate and bladder cancer, secreted CLU is
associated with tumour progression and used as a biomarker
of the disease.5,30 Secreted CLU could be involved in survival
signalling by modulating the Pi3K pathways or by behaving
like an extracellular chaperone, as described in this study and
previous investigations.2,14 However, genetic ablation of the
CLU gene, which causes the loss of both intracellular and
extracellular CLU isoforms, causes increased tumourigenesis
in mice, indicating that the intracellular form could have a
dominant tumour-suppressive role.19,20 In neuroblastoma,
secreted and intracellular CLU are likely to have a different
role. We have previously observed that in the presence of a
CLU-blocking antibody, neuroblastoma cells are sensitised to
doxorubicin killing, suggesting that secreted CLU is a survival
factor and potential oncogene.31 In spite of this, disruption
of the CLU gene causes increased tumourigenesis in
neuroblastoma prone mice.20
The logical conclusion of these observations is that
intracellular and extracellular CLU must have an opposing
role in tumourigenesis and cell signalling, and the purpose of
this study was to validate this hypothesis in a coherent
system.
The observations in the literature and those presented in
this work support the hypothesis that secreted and intracel-
lular CLU have different biological functions: the former
activates a survival programme, whereas the latter interferes
with the activity of protooncogenes such as NF-kB and
HSP60. By mass spectrometry and co-immunoprecipitation
experiments, we have identified HSP60 as a new CLU-
interacting partner and a potential neuroblastoma oncogene.
HSP60 is a chaperonin protein generally increased in cancer
and its cytosolic form inhibits apoptosis by activating
NF-kB.27,28,32 We show that ablation of HSP60 by RNA
interference causes increased apoptosis upstream of CLU,
demonstrating that in neuroblastoma there is an HSP60–CLU
axis with an antagonistic role in NF-kB regulation. This axis is
likely to have clinical relevance, as shown by the significant
association of elevated HSP60 and NF-kB target genes with
disease outcome.
Another interesting observation presented in this study is
that CLU isoforms are modulated during tumourigenesis.
After transformation, human and mouse cells show increased
expression of secreted CLU at the expense of the intracellular
precursor, corroborating the hypothesis that secreted CLU is
oncogenic, whereas intracellular CLU is tumour suppressive.
We believe that the observations presented in this study are
a further step towards a better understanding of the role of
CLU in cancer, reconciling some of the controversies
surrounding this interesting molecule.
Materials and Methods
Cell culture. WI-38, VA-13, SHSY-5Y, LA-N-1 and 293FT were all obtained
from the American Type Culture Collection, ATCC (Middlesex, UK) and maintained
in culture with Dulbecco’s Modified Eagle Medium supplemented with 10%
Figure 4 HSP60 and CLU form a complex in neuroblastoma cells. (a) Western blot analysis of LA-N-1 cell lysate showing expression of CLU at different time points after a
sub-lethal heat shock. Actin and HSP60 expression were used as a loading control. (b) Reciprocal co-immunoprecipitation of heath shocked LA-N-1 cells with CLU, HSP60
and control antibodies. The native CLU/HSP60 complex is indicated by the arrows. Inp, input
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heat-inactivated foetal bovine serum (FBS), 2 mM L-glutamine, penicillin (100 mg/
ml), streptomycin (100mg/ml) and 1% (10mM) MEM non-essential amino acid
(NEAA). All cell lines were purchased from the Primary human neuroblastoma
(IP-hNB1, hereafter referred to as HNB) cells were isolated from a tumour
metastasised in the neck of a 3-year-old male patient. HNB cells were cultured in
RPMI-1640 medium supplemented with 20% heat-inactivated foetal calf serum,
2mM L-glutamine, 10mM 2-mercaptoethanol, 1 mM sodium pyruvate, penicillin
(100mg/ml), streptomycin (100mg/ml) and 1% (10mM) NEAA. All media and sera
were purchased from Invitrogen (Paisley, UK).
Transfection and generation of conditioned media. 293 FT cells
(1 106 cells per 100mm dish) were plated and transiently transfected with 15 mg
empty MIG or CLU-MIG vectors using lipofectamine 2000, as described in the
manufacturer’s protocol. After 16 h, medium (supplemented with 0.5% FBS) was
replaced and cells were kept in a humidified incubator at 371C and 5% CO2 for 24 h
before conditioned media were collected and used in the luciferase assay
experiments.
Purified human recombinant CLU was purchased from Alexis (Exeter, UK).
Lentiviral constructs and infections. For lentiviral shRNA expression,
viral particles were produced in 293FT cells transfected with appropriate packaging
plasmids. pGIPZ lentiviral vector was obtained from Open Biosystems, Surrey, UK.
The non-silencing shRNAmir construct (scrambled shRNA) served as the negative
control. After 24 h of transfection, supernatants were collected, supplemented with
8mg/ml of polybrene (Sigma, Dorset, UK) and filtered through a 0.45-mm filter unit
to remove cell debris. Target cells were infected for 24 h at 371C.
Figure 5 HSP60 positively regulates proliferation and survival of established and primary neuroblastoma cell lines. (a) Western blot analysis to monitor the expression of
HSP60 in three SHSY-5Y cell clones obtained after infection with shRNA control (þ ) or HSP60 () targeting viruses. Quantification of HSP60 expression relative to actin is
shown in the bottom of the gel. (b) Fluorescence microscopy analysis to visualise GFP expression of the SHSY-5Y clones shown in (a). Pictures were taken the day after
infections (t 0) or after 6 days in culture (t 6). (c) Quantification of the experiment shown in (b). (d) Western blot analysis of primary human neuroblastoma cells infected with a
control (þ ) or HSP60 () shRNA lentivirus. Relative expression of HSP60 is indicated at the bottom of the gel. (e) Proliferation assay of primary human neuroblastoma cells
after ablation of HSP60 expression. (f) PI staining and FACS analysis to assess cell cycle profile and DNA fragmentation in primary human neuroblastoma cells after
downregulation of HSP60. Percentages of cells in the different phases of the cell cycle or subG1 DNA (fragmented DNA) are indicated
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Immunoblotting. Proteins were quantified by the dye-fixation Bradford
method (Sigma-Aldrich, Poole, UK), and the protein bands were resolved by 10%
SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes (GE Healthcare, Buckinghamshire, UK). After blocking with 5% dry
milk in PBS containing 0.1% NP40, membranes were incubated with the following
antibodies diluted in blocking buffer: clusterin (M-18, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) (1 : 500 dilution), actin (I-19, Santa Cruz Biotechnology)
(1 : 500 dilution), HSP60 (H-300, Santa Cruz Biotechnology) (1 : 500 dilution),
phospho-AKT (SER473, Cell Signaling Technology, Danvers, MA, USA) (1 : 1000
dilution), AKT (Cell Signaling Technology) (1 : 1000 dilution), GAPDH (Cell Signaling
Technology) (1 : 1000 dilution), phospho-ERK (Thr202/Tyr204, Cell Signaling
Technology) (1 : 2000 dilution) and ERK (Cell Signaling Technology) (1 : 1000
dilution). The membranes were then incubated with a secondary antibody: HRP-
conjugated anti-mouse IgG (1 : 10 000 dilution), HRP-conjugated anti-rabbit IgG
(1 : 10 000 dilution) or HRP-conjugated anti-goat IgG (1 : 10 000 dilution), all by
Amersham Bioscience (Buckinghamshire, UK). Antibody binding was detected by
enhanced chemiluminescence (GE Healthcare).
Preparation of tissues fromMYCN transgenicmice. Mice were killed
by cervical dislocation or CO2 asphyxiation when a palpable tumour was detected or
at the first signs of discomfort or stress, which is indicative of disease. Four
abdominal tumours originating in the adrenal glands of two females and two males
mice were excised and snap-frozen in liquid nitrogen for subsequent protein
analysis. Adrenal glands were isolated from four males and four females non-
transgenic CBA miceo3 months old. All experimental procedures involving mice
were approved by the University College London and were conducted under the
Animal (Scientific Procedures) Act, 1986 (United Kingdom).
Propidium iodide staining andFACSanalysis. Cells were fixed in cold
70% ethanol for at least 30min, centrifuged at 2000 r.p.m. for 5 min at room
temperature and washed twice in 1 ml phosphate–citrate buffer (0.2 M Na2HPO4
and 0.1 M citric acid) at room temperature. Cells were resuspended in PBS
containing ribonuclease A and propidium iodide (PI). Cells were incubated for
30min on ice. Samples were analysed using a cytofluorimeter BD LSR II (Becton
Dickinson, Oxford, UK).
GST fusion protein and pull-down assay. To generate GST fusion
constructs, PCR products containing the full-length human CLU, or the alpha and
beta chains were digested and ligated into pGEX4T-1 (GST) empty vectors to
create GST fusion protein expression vectors (pGEX4T-1–CLU, pGEX4T-1–alpha,
pGEX4T-1–beta). PCR was performed with the following primers: CLU forward
50-ACGCGTCGACACATGTCCAATCAGGGAAGTAAG-30; CLU reverse 50-TT
CGCCGGCGTCTCACTCCTCCCGGTGCTTTTT-30; CLU (beta chain) forward
50-ACGCGTCGACACATGAGCTTGATGCCCTTCTCTCCG-30; CLU (alpha chain)
reverse 50-TTCGGCGGCGTCTCAGCGGACGATGCGGGACTTGGG-30. The PCR
products contained the restriction site SalI and NotI (underlined).
GST, GST–CLU, GST–alpha (a) and GST–beta (b) were transformed into the
Escherichia coli strain BL21. Bacterial lysates were clarified by centrifugation, and
GST fusion proteins were purified on glutathione-Sepharose beads following
manufacturer’s instructions (GE Healthcare).
For pull-down assays, LA-N-1 (8 106) cells were harvested and resuspended
on ice in 200ml of bead-binding buffer A (50mM KH2PO4 (pH 7.5), 150mM KCl,
1 mM MgCl2) containing protease inhibitor (Roche, West Sussex, UK) and
sonicated for 10 s. After sonication, 200ml of bead-binding buffer B (50mM KH2PO4
(pH 7.5), 150mM KCl, 1 mM MgCl2, 20% glycerol and 2% triton- 100) containing
protease inhibitor (Roche) was added to the cells. Approximately 30 mg of total
cellular proteins were first precleared with glutathione-Sepharose beads and then
incubated for 1 h at 41C with immobilized GST fusion proteins. Unbound proteins
were removed by washing four times with 1ml of bead-binding buffer C (50mM
KH2PO4 (pH 7.5), 150mM KCl, 1 mM MgCl2, 10% glycerol and 1% triton- 100)
containing protease inhibitors (Roche). After the final wash, GST fusion protein
beads were boiled in 1 SDS sample-loading buffer and resolved on a 10%
polyacrylamide gel. Brilliant blue G-colloidal concentrate was purchased from Sigma
for the staining of proteins in the polyacrylamide gels. The staining was performed
according to the manufacturer’s protocol. Subsequently, the gel was destained in
10% acetic acid in 25% (v/v) methanol for 60 s with shaking. The gel was rinsed
twice with 25% methanol and scanned at 600 nm by Bio-Rad (Hertfordshire, UK)
quantity one programme.
Mass-spectrometry. Bands of interest were excised and an in-gel trypsin
digestion was carried out. Each band was destained using 200mM ammonium
bicarbonate with 20% acetonitrile, followed by reduction with 10mM dithiothreitol
(Melford Laboratories Ltd, Suffolk, UK), alkylation with 100mM iodoacetamide
(Sigma) and enzymatic digestion with sequencing grade modified porcine trypsin
(Promega, Southampton, UK) using an automated digest robot (Multiprobe II Plus
EX, Perkin Elmer, Cambridge, UK).
Figure 6 HSP60 is a negative prognostic marker in human neuroblastoma.
(a) Box plot showing the significant association between MYCN amplification and
HSP60 expression in 101 neuroblastoma patients. Data were mined through the
Oncomine website (http://www.Oncomine.org). Kaplan–Meier survival curves were
generated from the Oncogenomics website (http://pob.abcc.ncifcrf.gov/cgi-bin/JK)
using the data extracted from the Oberthuer. Black dots indicate outliers. (b) and
Seeger (c) affymetrix datasets
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Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) was
carried out upon each sample using a 4000 Q-Trap mass spectrometer (Applied
Biosystems, Warrington, UK). Peptides resulting from in-gel digestion were loaded
at high-flow rate onto a reverse-phase trapping column (0.3 mm i.d.  1mm),
containing 5 mm C18 300˚ Acclaim PepMap media (Dionex, Surrey, UK) and eluted
through a reverse-phase capillary column (75 mm i.d.  150mm) containingWaters
Symmetry C18 100˚ media (Waters, Hertfordshire, UK) that was self-packed using a
high pressure packing device (Proxeon Biosystems, Odense, Denmark). The output
from the column was sprayed directly into the nanospray ion source of the 4000 Q-
Trap mass spectrometer.
Fragment ion spectra generated by LC-MS/MS were searched using the
MASCOT search tool against the UniProtKB/Swiss-Prot protein database using
appropriate parameters. The criteria for protein identification were based on the
manufacturer’s definitions (Matrix Science Ltd, London, UK). Basically candidate
peptides with probability-based Mowse scores exceeding threshold (Po0.05), and
thus indicating a significant or extensive homology were referred to as ‘hits’. Protein
identifications were only considered if they contained three or more peptides with
scores4Po0.05 threshold.
Co-immunoprecipitation. 293FT cells (1 106 cells in 100mm dish) were
transiently transfected with pcDNA3-empty or pcDNA3-CLU (full length) using
LipofectAMINE 2000 (Invitrogen). The culture media were replaced on the next day
with additional of 20mM MG132 (C2211, Sigma) and 48 h after transfection, cells
were rinsed in ice-cold PBS twice before 1ml of ice-cold non-denaturing lysis buffer
(50mM Tris-Cl, (pH 7.5), 150mM NaCl, 1 mM EDTA, 1% (v/v) Triton-X100
containing protease and phosphatase inhibitors (Roche) was added to the plates.
The cell lysate was precleared with Protein G sepharose 4B (GE Healthcare) for
30min on a rotator at 41C to minimise non-specific binding. After preclearing,
immunoprecipitation was performed by incubating equal amount of whole-cell
protein extracts (15 mg) with 2mg of anti-CLU (M-18), anti-HSP60 (H-300)
antibodies or normal goat and rabbit IgGs (Santa Cruz Biotechnology) for 1 h on a
rotator at 41C. The immune complexes were collected by incubating protein
G-sepharose 4B for 16 h on a rotator at 41C and then washing it five times in PBS.
The bound proteins were resuspended in 1 SDS sample buffer and applied to
western blot with anti-HSP60 antibody. All steps were carried out on ice.
Luciferase assays. For dual luciferase assay, cells (5 104/well in a 24-well
plate) were plated 24 h before being transiently cotransfected with 200 ng of the
NF-kB LUC reporter plasmid and 5 ng of renilla luciferase vector (Promega) with or
without 400 mg of empty MIG or CLU-MIG plasmids21 using LipofectAMINE 2000
(Invitrogen). After 16 h, the transfection mixture media was replaced by fresh media
containing TNF-a (10 mg/ml) (Invitrogen). Cells were harvested 8 h later and
luciferase assays were carried out with a kit (Promega) following manufacturer’s
instructions. Light emission was measured with a Lumat LB9507 (Berthold
Technologies, Hertfordshire, UK).
Annexin-V staining. Annexin V conjugate (Annexin V AlexaFluor 647,
Invitrogen) was diluted with Annexin V-binding buffer (BD Biosciences Pharmingen,
Figure 7 Downregulation of CLU rescues apoptosis induced by ablation of HSP60. Cell cycle profiles and DNA fragmentation (indicated by percentages of subG1 DNA, in
bold) were assessed by flow cytometry after knockdown of CLU and HSP60 in SHSY-5Ycell clones. The experiment was repeated twice. (a) experiment 1; (b) experiment 2.
Quantification of the percentages of cells showing fragmented DNA in the different conditions is shown in the right of each panel
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San Diego, CA, USA) at the ratio of 1 : 200. The cell pellets were then resuspended
in 300ml of the Annexin V conjugate/binding buffer mixture. Cells were mixed gently
to ensure equal staining and the samples were kept on ice in the dark for 20min.
Before FACS analysis, 30ml of 50mg PI solution was added to each sample. The
samples were analysed by a BD LSR II (Becton Dickenson, Oxford, UK).
Statistical analysis. All experiments were repeated in triplicate (n¼ 3),
unless otherwise stated. Statistical analysis was carried out using a Student-t-test
(unpaired, two-tailed). P-values ofr0.05 were considered significant.
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